2nd Quarter - Report

W STRATEGIES, LLC for ALEXION PHARMACEUTICALS

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Monitoring the implementation of the Korea-U.S. Free Trade Agreement, as it relates to transparency in Korean government coverage and reimbursement of biologics.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

S. 2236: Advancing Breakthrough Therapies for Patients Act. H.R. 5651: Food and Drug Administration Reform Act of 2012. S. 3187: Food and Drug Administration Safety and Innovation Act of 2012. H.R. 4132: Faster Access to Specialized Treatments Act. Federal legislative efforts to enhance the security and integrity of the domestic pharmaceutical distribution system.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 2236 (112th), H.R. 4132 (112th), H.R. 5651 (112th), S. 3187 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.